Want to see NUS full AI Analyst Report?
Earnings Data
Report Date
Aug 05, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
0.2Last Year’s EPS
0.43Same Quarter Last Year
Based on 0 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call balanced meaningful early strategic progress (Prysm iO data scale, subscription growth, LifePak +10% growth, regional momentum, and a strengthened balance sheet) against near-term profitability pressures (operating margin decline, higher selling expense, macro and transition costs). Management maintained guidance, signaled sequential improvement for Q2, and emphasized disciplined execution while investing in long-term growth initiatives.Company Guidance
Revenue in Line with Guidance
Q1 revenue of $320.6 million was within guidance, including a 1% favorable foreign currency impact, and management maintained full-year guidance with more clarity expected after Q2.
Adjusted EPS in Line with Expectations
Adjusted earnings per share were $0.14 for the quarter (GAAP EPS $0.04), reported as in-line with guidance after excluding charges related to winding down the BeautyBio business and other items.
Prysm iO Early Adoption and Data Scale
Nearly 2 million Prysm iO scans from over 30,000 devices (plus 20 million historical biophotonics scans) demonstrating early traction; subscription volume up 5% year-over-year and subscribers as a percent of total customers up 14% year-over-year.
Nutrition Ecosystem Strength and Product Growth
Products certified to raise Prysm iO scores are outperforming total product sales; flagship LifePak brand grew more than 10% year-over-year, supporting measurement-based wellness strategy.
Regional Momentum in Key Markets
Sustained growth in Latin America and continued improvement in Mainland China with leader engagement around Tru Face anti-aging rollout; management also progressing pre-market efforts in India for a planned formal launch later in the year.
Balance Sheet and Capital Return Actions
Completed refinancing extending credit maturities through 2031 and improving cost of borrowing; returned approximately $8 million to shareholders (dividends $3M, repurchases $5M) with $137.3 million remaining under repurchase authorization.
Gross Margin Progress in Core Business
Core Nu Skin gross margin improved to 76.9%, up 20 basis points year-over-year; consolidated adjusted gross margin was 67.9% versus 67.8% prior year (stable).
Forward Revenue and EPS Guidance Shows Sequential Improvement
Q2 guidance calls for revenue of $330M to $360M and EPS of $0.15 to $0.25, reflecting management's expectation of sequential improvement from Q1.
NUS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
NUS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2026 | $6.95 | $7.09 | +2.00% |
Feb 12, 2026 | $10.04 | $8.22 | -18.12% |
Nov 06, 2025 | $10.59 | $8.91 | -15.79% |
Aug 07, 2025 | $7.97 | $8.68 | +8.90% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Nu Skin Enterprises (NUS) report earnings?
Nu Skin Enterprises (NUS) is schdueled to report earning on Aug 05, 2026, After Close (Confirmed).
What is Nu Skin Enterprises (NUS) earnings time?
Nu Skin Enterprises (NUS) earnings time is at Aug 05, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is NUS EPS forecast?
NUS EPS forecast for the fiscal quarter 2026 (Q2) is 0.2.